Sept. 16 Company Quick Takes: FDA accepts Seattle Genetics' BLA; plus Akynzeo, Purdue, Amplyx, Abbott-Sanofi

FDA to review enfortumab vedotin
Seattle Genetics Inc. (NASDAQ:SGEN) and partner Astellas Pharma Inc. (JASDAQ:4503) said FDA has accepted a BLA and granted Priority Review to enfortumab vedotin for locally

Read the full 299 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE